News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 Archive March 16, 2015 Deciphera Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference Archive November 20, 2014 Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701), an Advanced Multi-targeted Kinase Inhibitor, at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Archive November 17, 2014 Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701) that Demonstrated Inhibition of Tumor Growth and Invasion in Bevacizumab Resistant Glioblastoma Archive June 30, 2014 Deciphera Pharmaceuticals Appoints Oliver Rosen M.D. as Chief Medical Officer Archive May 30, 2014 Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors Archive April 7, 2014 Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 Pan-RAF Inhibitor Created and Developed in Collaboration with Eli Lilly Archive April 7, 2014 Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer Archive March 17, 2014 Deciphera Pharmaceuticals Presents Preclinical Data on Rebastinib and DCC-3014 at AACR Tumor Microenvironment Conference Archive August 5, 2013 Deciphera announces appointment of John de Groot, MD to its Scientific Advisory Board Archive July 27, 2013 Deciphera announces appointment of John Condeelis to its Scientific Advisory Board
Archive March 16, 2015 Deciphera Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
Archive November 20, 2014 Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701), an Advanced Multi-targeted Kinase Inhibitor, at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Archive November 17, 2014 Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701) that Demonstrated Inhibition of Tumor Growth and Invasion in Bevacizumab Resistant Glioblastoma
Archive May 30, 2014 Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors
Archive April 7, 2014 Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 Pan-RAF Inhibitor Created and Developed in Collaboration with Eli Lilly
Archive April 7, 2014 Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
Archive March 17, 2014 Deciphera Pharmaceuticals Presents Preclinical Data on Rebastinib and DCC-3014 at AACR Tumor Microenvironment Conference
Archive August 5, 2013 Deciphera announces appointment of John de Groot, MD to its Scientific Advisory Board
Archive July 27, 2013 Deciphera announces appointment of John Condeelis to its Scientific Advisory Board
